We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

BECKMAN COULTER, INC.

  Gold Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Sep 2020 - 09 Sep 2020
Virtual Venue

Eosinophil Count Provides Diagnostic Information for COVID-19

By LabMedica International staff writers
Posted on 29 Jul 2020
Print article
Image: The Multisizer 4e Coulter Counter is a highly versatile particle counting and characterization system (Photo courtesy of Beckman Coulter).
Image: The Multisizer 4e Coulter Counter is a highly versatile particle counting and characterization system (Photo courtesy of Beckman Coulter).
Early diagnosis of coronavirus disease 2019 (COVID-19) and patient isolation are important for both individual patient care and disease containment. The diagnosis is confirmed by testing for the presence of nasopharyngeal viral RNA with a polymerase chain reaction assay, which has limited availability, variable turnaround time, and a high false-negative rate.

Laboratory parameters, such as lymphopenia and elevated concentrations of liver enzymes, C-reactive protein, lactate dehydrogenase, ferritin, and D-dimer, have been associated with COVID-19 and some, such as elevated levels of C-reactive protein and D-dimer, have been linked to the severity of the disease. One report observed a progressive decline in the lymphocyte count in non-survivors compared with more stable levels in survivors.

Scientists at Coney Island Hospital (Brooklyn, NY, USA) compared the eosinophil results of routine complete blood counts (CBC) from the first 50 admitted COVID-19–positive patients were compared with the eosinophil results of 50 patients with confirmed influenza infection at the time of presentation to the emergency department. The number of patients with zero eosinophils on the day of presentation was also compared between the two groups. Furthermore, the eosinophil counts in the 50 COVID-19 patients were reviewed for the first five days of their hospital stay and before discharge, along with the outcome (deceased versus discharged), and trends in eosinophil data were compared based on the outcome. Eosinophils were determined by the Coulter counter (Beckman Coulter, Indianapolis, IN, USA) and its lower limit of detection of eosinophils is zero.

The investigators reported that on the day of presentation, 30 patients in the COVID-19 group (60%) and eight patients in the influenza group (16%) had an eosinophil count of zero. An additional 14 patients in the COVID-19 group had zero eosinophils during the following two days; the total number of patients in the COVID-19 group who had zero eosinophils on admission or during the ensuing two days was 44 (88%). In addition, 18 of 21 deceased patients in the COVID-19 group (86%) who initially presented with eosinopenia remained eosinopenic compared with 13 of 26 survivors (50%).

Muhammad M. Zaman, MD, an infectious disease specialist and senior author of the study said, “Review of the eosinophil count can be a useful tool in deciding whether to promptly isolate someone and initiate specific therapies while waiting for confirmatory test results. In COVID-19, a disease that has substantial symptom overlap with influenza, eosinopenia could help to distinguish which patients likely have COVID-19.”

The authors concluded that the existing COVID-19 PCR diagnostic test has limitations, limited availability, variable turnaround time, and a high false-negative rate. An eosinophil count of zero in patients requiring hospitalization can assist in the early recognition of COVID-19 and be used to direct therapeutic decisions while confirmatory PCR tests are still in process. These findings may be especially helpful during seasons when influenza infection is prevalent and symptom-based patient classification may lack specificity in diagnosing COVID-19. Poor improvement of eosinophil counts after admission was also correlated with high disease severity and with low rates of recovery. The study was published on July 16, 2020 in The Journal of the American Osteopathic Association.





Print article

Channels

Molecular Diagnostics

view channel
Image: The NovaSeq 6000 Sequencing System offers high-throughput sequencing across a broad range of applications (Photo courtesy of Illumina).

Somatic Evolution Identified in Non-Neoplastic IBD-Affected Colon

Inflammatory bowel disease (IBD) is a debilitating disease characterized by repeated flares of intestinal inflammation. The two major subtypes of IBD, Crohn’s disease (CD) and ulcerative colitis (UC) are... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.